Other OTC - Delayed Quote • USD
Immunotech Laboratories, Inc. (IMMB)
At close: March 18 at 2:01 PM EDT
Key Executives
Amounts are as of December 31, 2009 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Harry H. Zhabilov Jr. | Founder, Vice Chairman, President, Chief Science Officer & Secretary | -- | -- | 1967 |
| Billy Ray | CFO, Executive of Business and Development & Member of Advisory Board | -- | -- | -- |
| Mr. Adam S. Tracy Esq., J.D., MBA | Legal Counsel | -- | -- | 1976 |
Immunotech Laboratories, Inc.
- Full Time Employees:
- 4
Description
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Eco-Petroleum Solutions, Inc.
Corporate Governance
Immunotech Laboratories, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
Recent Events Information Not Available
Upcoming Events
Upcoming Events Information Not Available